Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement.

Zheng D, Zeng F, Cai A, Liao H, Liu L, Qiu R, Xu R, Xiao C, Mai W.

Lipids Health Dis. 2014 Mar 1;13:41. doi: 10.1186/1476-511X-13-41.

PMID:
24580749
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients.

Maiolino G, Pedon L, Cesari M, Frigo AC, Wolfert RL, Barisa M, Pagliani L, Rossitto G, Seccia TM, Zanchetta M, Rossi GP.

PLoS One. 2012;7(10):e48171. doi: 10.1371/journal.pone.0048171. Epub 2012 Oct 31.

PMID:
23118945
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.

Sabatine MS, Morrow DA, O'Donoghue M, Jablonksi KA, Rice MM, Solomon S, Rosenberg Y, Domanski MJ, Hsia J; PEACE Investigators.

Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2463-9. Epub 2007 Aug 31.

PMID:
17766330
[PubMed - indexed for MEDLINE]
Free Article
4.

Baseline LDL-C and Lp(a) elevations portend a high risk of coronary revascularization in patients after stent placement.

Cai A, Li L, Zhang Y, Mo Y, Li Z, Mai W, Zhou Y.

Dis Markers. 2013;35(6):857-62. doi: 10.1155/2013/472845. Epub 2013 Dec 3.

PMID:
24367139
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.

Charniot JC, Khani-Bittar R, Albertini JP, Giral P, Cherfils C, Cosson C, Guillerm E, Leprince P, Gandjbakhch I, Bonnefont-Rousselot D.

Int J Cardiol. 2013 Sep 20;168(1):132-8. doi: 10.1016/j.ijcard.2012.09.054. Epub 2012 Oct 24.

PMID:
23103135
[PubMed - indexed for MEDLINE]
6.

Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.

Persson M, Hedblad B, Nelson JJ, Berglund G.

Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1411-6. Epub 2007 Apr 12.

PMID:
17431184
[PubMed - indexed for MEDLINE]
Free Article
7.

Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study.

Daniels LB, Laughlin GA, Sarno MJ, Bettencourt R, Wolfert RL, Barrett-Connor E.

J Am Coll Cardiol. 2008 Mar 4;51(9):913-9. doi: 10.1016/j.jacc.2007.10.048.

PMID:
18308160
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.

Jabor B, Choi H, Ruel I, Hafiane A, Mourad W, Genest J.

Can J Cardiol. 2013 Dec;29(12):1679-86. doi: 10.1016/j.cjca.2013.09.026. Epub 2013 Oct 2.

PMID:
24267807
[PubMed - indexed for MEDLINE]
9.

Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis.

Kolasa-Trela R, Fil K, Bazanek M, Grudzień G, Sobczyk D, Sadowski J, Undas A.

Clin Chem Lab Med. 2012 Oct 1;50(10):1825-31. doi: 10.1515/cclm-2012-0015.

PMID:
23089713
[PubMed - indexed for MEDLINE]
10.

Low basal levels of circulating adiponectin in patients undergoing coronary stenting predict in-stent restenosis, independently of basal levels of inflammatory markers: lipoprotein associated phospholipase A2, and myeloperoxidase.

Moldoveanu E, Mut-Vitcu B, Tanaseanu GR, Marta DS, Manea G, Kosaka T, Vidulescu C, Tanaseanu C.

Clin Biochem. 2008 Dec;41(18):1429-33. doi: 10.1016/j.clinbiochem.2008.09.109. Epub 2008 Oct 7.

PMID:
18930040
[PubMed - indexed for MEDLINE]
11.

Association of lipoprotein-associated phospholipase A2 with coronary calcification among American and Japanese men.

El-Saed A, Sekikawa A, Zaky RW, Kadowaki T, Takamiya T, Okamura T, Edmundowicz D, Kita Y, Kuller LH, Ueshima H.

J Epidemiol. 2007 Nov;17(6):179-85.

PMID:
18094516
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort.

Li N, Li S, Yu C, Gu S.

Postgrad Med. 2010 Jul;122(4):200-5. doi: 10.3810/pgm.2010.07.2187.

PMID:
20675983
[PubMed - indexed for MEDLINE]
14.

Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome.

Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Ohkawa R, Nakamura K, Yanagisawa N, Tsuboi S, Ogita M, Yokoyama K, Kurata T, Yatomi Y, Daida H.

Atherosclerosis. 2011 Dec;219(2):907-12. doi: 10.1016/j.atherosclerosis.2011.09.019. Epub 2011 Sep 17.

PMID:
22024276
[PubMed - indexed for MEDLINE]
15.

The effect of statin therapy on lipoprotein associated phospholipase A2 levels.

Albert MA, Glynn RJ, Wolfert RL, Ridker PM.

Atherosclerosis. 2005 Sep;182(1):193-8.

PMID:
15982658
[PubMed - indexed for MEDLINE]
16.

Lipoprotein-associated phospholipase A2 and coronary calcification. The Rotterdam Coronary Calcification Study.

Kardys I, Oei HH, Hofman A, Oudkerk M, Witteman JC.

Atherosclerosis. 2007 Apr;191(2):377-83. Epub 2006 May 4.

PMID:
16678183
[PubMed - indexed for MEDLINE]
17.
18.

Utility of lipoprotein-associated phospholipase A2 for prediction of 30-day major adverse coronary event in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.

Stankovic S, Asanin M, Trifunovic D, Majkic-Singh N, Miljković A, Ignjatovic S, Mrdovic I, Matic D, Savic L, Ostojic M, Vasiljevic Z.

Clin Lab. 2012;58(11-12):1135-44.

PMID:
23289182
[PubMed - indexed for MEDLINE]
19.

Is lipoprotein-associated phospholipase A2 activity correlated with fibrous-cap thickness and plaque volume in patients with acute coronary syndrome?

Gu X, Hou J, Yang S, Yu H, Tian J, Liu F, Li N, Yu B, Jang IK.

Coron Artery Dis. 2014 Jan;25(1):10-5. doi: 10.1097/MCA.0000000000000041.

PMID:
24089018
[PubMed - indexed for MEDLINE]
20.

Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.

White HD, Simes J, Stewart RA, Blankenberg S, Barnes EH, Marschner IC, Thompson P, West M, Zeller T, Colquhoun DM, Nestel P, Keech AC, Sullivan DR, Hunt D, Tonkin A; LIPID Study Investigators.

J Am Heart Assoc. 2013 Oct 23;2(5):e000360. doi: 10.1161/JAHA.113.000360.

PMID:
24152981
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk